Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus casei LBC80R
- Development stage
- Unknown
- Lead developer
- Kerry
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus casei LBC80R is a proprietary probiotic strain of the species *Lacticaseibacillus casei* (formerly *Lactobacillus casei*) developed by Bio-K+. It is a primary component of the Bio-K+ probiotic product line, which typically features a combination of three strains: L. casei LBC80R, L. rhamnosus CLR2, and L. acidophilus CL1285. The strain is designed to support digestive and immune health by modulating the intestinal microbiota, enhancing the gut barrier function, and competing with pathogens for nutrients and adhesion sites. Clinical studies have demonstrated that the Bio-K+ multi-strain formula is effective in reducing the risk of antibiotic-associated diarrhea (AAD) and Clostridioides difficile infections (CDI) in hospitalized patients. It is commercially available in various oral formats, including fermented dairy and soy beverages as well as enteric-coated capsules.
- Brand names
- Bio-K+
- Other names
- L. casei LBC80RLacticaseibacillus casei LBC80RLactobacillus casei LBC80R®
Beyond the preview
Go deeper on Lactobacillus casei LBC80R.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus casei LBC80R.